modelInterferonBeta1b

Diagram of InterferonBeta1b

Extends from Pharmacolibrary.Drugs.ATC.L.L03AB08.

Information

name:InterferonBeta1b
ATC code:L03AB08
route:subcutaneous
compartments:2
dosage:0.25mg
volume of distribution:0.25L
clearance:33L/h
other parameters in model implementation

Interferon beta-1b is a recombinant form of human interferon beta used as an immunomodulatory agent in the treatment of relapsing forms of multiple sclerosis (MS). It functions by modifying the immune response and reducing inflammation. Interferon beta-1b is an FDA- and EMA-approved medication that has been in clinical use for MS for several decades.

Pharmacokinetics

Pharmacokinetic parameters following subcutaneous administration of 250 micrograms in healthy adult volunteers.

References

  1. Connelly, JF (1994). Interferon beta for multiple sclerosis. The Annals of pharmacotherapy 28(5) 610–616. DOI:10.1177/106002809402800511 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8069001

  2. Johnston, J, & So, TY (2012). First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview. Drugs 72(9) 1195–1211. DOI:10.2165/11634010-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22642799

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)